4 Stocks Make It On Today's Healthcare & Biotech Stock Watchlist
Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
GE HealthCare Technologies Inc., GEHC
Summary: Chicago, IL-based GE Healthcare is a leading maker of medical imaging and patient-monitoring products and related equipment and services. Approximately half of GE Healthcare's revenue comes from equipment sales, with consumables and services accounting for the other half. GE Healthcare started operating as an independent company after its January 2023 spin-off from General Electric (GE).
- Last Price: $79.80
- Price Change: $0.33, 0.42%
- Yearly Gain: 0.48%
- Market Cap: $36.43B
- P/E Ratio: 23.2
Here are 3rd party ratings for GEHC:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 40% (100 out of 252)
What is the sentiment on the street regarding GE HealthCare Technologies Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in GEHC or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on GEHC before you decide to make any investment.
Click here for chart >>
Neurocrine Biosciences, Inc., NBIX
Summary: Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.
- Last Price: $141.71
- Price Change: $1.00, 0.71%
- Yearly Gain: 44.75%
- Market Cap: $14.26B
- P/E Ratio: 38.4
Here are 3rd party ratings for NBIX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 39% (98 out of 252)
What is the sentiment on the street regarding Neurocrine Biosciences, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Strong Buy
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in NBIX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on NBIX before you decide to make any investment.
Click here for chart >>
Ligand Pharmaceuticals Incorporated, LGND
Summary: Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.
- Last Price: $72.83
- Price Change: $-1.07, -1.45%
- Yearly Gain: -5.97%
- Market Cap: $1.31B
- P/E Ratio: 24.04
Here are 3rd party ratings for LGND:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Strong Buy, Top 32% (80 out of 252)
What is the sentiment on the street regarding Ligand Pharmaceuticals Incorporated ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Buy
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in LGND or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on LGND before you decide to make any investment.
Click here for chart >>
AtriCure, Inc., ATRC
Summary: AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart.
- Last Price: $22.10
- Price Change: $1.21, 5.79%
- Yearly Gain: -53.73%
- Market Cap: $1.07B
- P/E Ratio: -33.48
Here are 3rd party ratings for ATRC:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Bottom 40% (151 out of 252)
What is the sentiment on the street regarding AtriCure, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Sell
- Insider Signal: Selling
- Investor Sentiment: Negative
- Hedge Fund signal: Medium Risk
If you are interested in ATRC or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on ATRC before you decide to make any investment.
Click here for chart >>
Thanks for reading!